Skip to main content
SpringerLink
Log in

Dendritic Cell Vaccines

  • Protocol
  • First Online:
Vaccine Design

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1403))

Abstract

Exploitation of the patient’s own immune system to induce antitumor immune responses using dendritic cell (DC) immunotherapy has been established in early clinical trials as a safe and promising therapeutic approach for cancer. However, their limited success in larger clinical trials highlights the need to optimize DC vaccine preparations. This chapter describes the methodologies utilized for the preparation of the DC vaccine most commonly used in clinical trials. Optional variations at different stages in DC vaccine preparation, based on the nature of antigen, delivery of antigen, maturation stimuli, and mode of administration for DC vaccines, are also presented for consideration as these are often dependent on the disease setting, desired immune response, and/or resources available.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Palucka K, Banchereau J (2013) Dendritic-cell-based therapeutic cancer vaccines. Immunity 39:38–48

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133–146

    Article  CAS  PubMed  Google Scholar 

  3. Vignali DA, Kuchroo VK (2012) IL-12 family cytokines: immunological playmakers. Nat Immunol 13:722–728

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. McKenna K, Beignon AS, Bhardwaj N (2005) Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol 79:17–27

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Drobits B, Holcmann M, Amberg N, Swiecki M et al (2012) Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest 122:575–585

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Gandhi RT, O’Neill D, Bosch RJ, Chan ES, Bucy RP, Shopis J et al (2009) A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 27:6088–6094

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F et al (2006) Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother 29:545–557

    Article  CAS  PubMed  Google Scholar 

  8. Redman BG, Chang AE, Whitfield J, Esper P et al (2008) Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J Immunother 31:591–598

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Sabado RL, Miller E, Spadaccia M, Vengco I, Hasan F, Bhardwaj N (2013) Preparation of tumor antigen-loaded mature dendritic cells for immunotherapy. J Vis Exp (78)

    Google Scholar 

  10. Miller E, Spadaccia M, Sabado R, Chertova E et al (2015) Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy. Vaccine 33: 388–395

    Article  CAS  PubMed  Google Scholar 

  11. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S et al (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61:6451–6458

    CAS  PubMed  Google Scholar 

  12. Marroquin CE, Westwood JA, Lapointe R, Mixon A et al (2002) Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells. J Immunother 25:278–288

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kantoff PW, Higano CS, Shore ND, Berger ER et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422

    Article  CAS  PubMed  Google Scholar 

  14. Small EJ, Schellhammer PF, Higano CS, Redfern CH et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:3089–3094

    Article  CAS  PubMed  Google Scholar 

  15. Sikora AG, Hailemichael Y, Overwijk WW (2012) Conference scene: immune effector mechanisms in tumor immunity. Immunotherapy 4:141–143

    Article  PubMed  Google Scholar 

  16. Adams S, O’Neill D, Bhardwaj N (2004) Maturation matters: importance of maturation for antitumor immunity of dendritic cell vaccines. J Clin Oncol 22:3834–3835

    Article  PubMed  Google Scholar 

  17. Lee AW, Truong T, Bickham K, Fonteneau JF et al (2002) A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy. Vaccine 20(Suppl 4):A8–A22

    Article  CAS  PubMed  Google Scholar 

  18. Jongmans W, Tiemessen DM, van Vlodrop IJ, Mulders PF, Oosterwijk E (2005) Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails. J Immunother 28:480–487

    Article  CAS  PubMed  Google Scholar 

  19. Krause P, Singer E, Darley PI, Klebensberger J et al (2007) Prostaglandin E2 is a key factor for monocyte-derived dendritic cell maturation: enhanced T cell stimulatory capacity despite IDO. J Leukoc Biol 82:1106–1114

    Article  CAS  PubMed  Google Scholar 

  20. Morelli AE, Thomson AW (2003) Dendritic cells under the spell of prostaglandins. Trends Immunol 24:108–111

    Article  CAS  PubMed  Google Scholar 

  21. Kwissa M, Nakaya HI, Oluoch H, Pulendran B (2012) Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates. Blood 119:2044–2055

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R (2001) Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2:947–950

    Article  CAS  PubMed  Google Scholar 

  23. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A (2005) Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6:769–776

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Boullart AC, Aarntzen EH, Verdijk P, Jacobs JF et al (2008) Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother 57:1589–1597

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Bogunovic D, Manches O, Godefroy E, Yewdall A et al (2011) TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. Cancer Res 71:5467–5476

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Mailliard RB, Wankowicz-Kalinska A, Cai Q et al (2004) alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 64:5934–5937

    Article  CAS  PubMed  Google Scholar 

  27. Lee JJ, Foon KA, Mailliard RB, Muthuswamy R, Kalinski P (2008) Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J Leukoc Biol 84:319–325

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Whitehurst AW (2014) Cause and consequence of cancer/testis antigen activation in cancer. Annu Rev Pharmacol Toxicol 54:251–272

    Article  CAS  PubMed  Google Scholar 

  29. Andrews MC, Woods K, Cebon J, Behren A (2014) Evolving role of tumor antigens for future melanoma therapies. Future Oncol 10: 1457–1468

    Article  CAS  PubMed  Google Scholar 

  30. Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348:69–74

    Article  CAS  PubMed  Google Scholar 

  31. Carreno BM, Magrini V, Becker-Hapak M et al (2015) A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348:803–808

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. O’Neill D, Bhardwaj N (2005) Generation of autologous peptide- and protein-pulsed dendritic cells for patient-specific immunotherapy. Methods Mol Med 109:97–112

    PubMed  Google Scholar 

  33. Melief CJ, van der Burg SH (2008) Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 8:351–360

    Article  CAS  PubMed  Google Scholar 

  34. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, van der Burg SH, Offringa R (2008) Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol 38:1033–1042

    Article  CAS  PubMed  Google Scholar 

  35. Barrou B, Benoit G, Ouldkaci M, Cussenot O et al (2004) Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother 53:453–460

    Article  PubMed  Google Scholar 

  36. Salcedo M, Bercovici N, Taylor R, Vereecken P et al (2006) Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother 55:819–829

    Article  CAS  PubMed  Google Scholar 

  37. Mahdian R, Kokhaei P, Najar HM, Derkow K, Choudhury A, Mellstedt H (2006) Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific antitumor T cells. Med Oncol 23:273–282

    Article  CAS  PubMed  Google Scholar 

  38. Schnurr M, Galambos P, Scholz C, Then F, Dauer M, Endres S, Eigler A (2001) Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res 61:6445–6450

    CAS  PubMed  Google Scholar 

  39. Thumann P, Moc I, Humrich J, Berger TG, Schultz ES, Schuler G, Jenne L (2003) Antigen loading of dendritic cells with whole tumor cell preparations. J Immunol Methods 277:1–16

    Article  CAS  PubMed  Google Scholar 

  40. Wheeler CJ, Black KL (2009) DCVax-Brain and DC vaccines in the treatment of GBM. Expert Opin Investig Drugs 18:509–519

    Article  CAS  PubMed  Google Scholar 

  41. Schnurr M, Chen Q, Shin A, Chen W, Toy T, Jenderek C et al (2005) Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 105:2465–2472

    Article  CAS  PubMed  Google Scholar 

  42. Jenne L, Schuler G, Steinkasserer A (2001) Viral vectors for dendritic cell-based immunotherapy. Trends Immunol 22:102–107

    Article  CAS  PubMed  Google Scholar 

  43. Brockstedt DG, Dubensky TW (2008) Promises and challenges for the development of Listeria monocytogenes-based immunotherapies. Expert Rev Vaccines 7:1069–1084

    Article  PubMed  Google Scholar 

  44. Bellone S, El-Sahwi K, Cocco E, Casagrande F et al (2009) Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines. J Virol 83:6779–6789

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Carrasco J, Van Pel A, Neyns B, Lethe B, Brasseur F et al (2008) Vaccination of a melanoma patient with mature dendritic cells pulsed with MAGE-3 peptides triggers the activity of nonvaccine anti-tumor cells. J Immunol 180:3585–3593

    Article  CAS  PubMed  Google Scholar 

  46. Butterfield LH, Comin-Anduix B, Vujanovic L et al (2008) Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother 31:294–309

    Article  PubMed  PubMed Central  Google Scholar 

  47. Veron P, Allo V, Riviere C, Bernard J, Douar AM, Masurier C (2007) Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2. J Virol 81:5385–5394

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Nair SK, Morse M, Boczkowski D, Cumming RI, Vasovic L, Gilboa E, Lyerly HK (2002) Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 235:540–549

    Article  PubMed  PubMed Central  Google Scholar 

  49. Muller MR, Tsakou G, Grunebach F, Schmidt SM, Brossart P (2004) Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. Blood 103: 1763–1769

    Article  PubMed  Google Scholar 

  50. Nencioni A, Muller MR, Grunebach F, Garuti A, Mingari MC, Patrone F, Ballestrero A, Brossart P (2003) Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer. Cancer Gene Ther 10:209–214

    Article  CAS  PubMed  Google Scholar 

  51. Milazzo C, Reichardt VL, Muller MR, Grunebach F, Brossart P (2003) Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 101:977–982

    Article  CAS  PubMed  Google Scholar 

  52. Gilboa E, Vieweg J (2004) Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 199:251–263

    Article  CAS  PubMed  Google Scholar 

  53. Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P, Vieweg J (2001) Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 61:3388–3393

    CAS  PubMed  Google Scholar 

  54. Strobel I, Berchtold S, Gotze A, Schulze U, Schuler G, Steinkasserer A (2000) Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther 7:2028–2035

    Article  CAS  PubMed  Google Scholar 

  55. Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J (2000) Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 165:5713–5719

    Article  CAS  PubMed  Google Scholar 

  56. Heiser A, Coleman D, Dannull J, Yancey D et al (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109:409–417

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Routy JP, Boulassel MR, Yassine-Diab B, Nicolette C et al (2010) Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol 134:140–147

    Article  CAS  PubMed  Google Scholar 

  58. Teijeira A, Russo E, Halin C (2014) Taking the lymphatic route: dendritic cell migration to draining lymph nodes. Semin Immunopathol 36:261–274

    Article  CAS  PubMed  Google Scholar 

  59. Verdijk P, Aarntzen EH, Lesterhuis WJ, Boullart AC et al (2009) Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 15:2531–2540

    Article  CAS  PubMed  Google Scholar 

  60. Fujiwara S, Wada H, Miyata H, Kawada J, Kawabata R et al (2012) Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer. J Immunother 35:513–521

    Article  CAS  PubMed  Google Scholar 

  61. Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ et al (2011) Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 17:5725–5735

    Article  CAS  PubMed  Google Scholar 

  62. Yewdall AW, Drutman SB, Jinwala F, Bahjat KS, Bhardwaj N (2010) CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS One 5(6):e11144

    Article  PubMed  PubMed Central  Google Scholar 

  63. Mitchell DA, Batich KA, Gunn MD, Huang MN et al (2015) Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519:366–369

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Garcia F, Climent N, Guardo AC, Gil C, Leon A, Autran B, Lifson JD, Martinez-Picado J, Dalmau J, Clotet B, Gatell JM, Plana M, Gallart T (2013) A dendritic cell-based vaccine elicits t cell responses associated with control of HIV-1 replication. Sci Transl Med 5(166):166ra162

    Article  Google Scholar 

Download references

Acknowledgements

We would like to thank Andres Salazar for providing the poly-ICLC. We would also like to thank the staff of the Vaccine and Cell Therapy Laboratory—Farah Hasan, Hanqing Dong, Bike Su Oner, and Marina Aziz—for the help in refining the procedure.

Author information

Authors and Affiliations

  1. Division of Hematology and Medical Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA

    Rachel Lubong Sabado, Marcia Meseck & Nina Bhardwaj

Authors
  1. Rachel Lubong Sabado
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcia Meseck
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nina Bhardwaj
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rachel Lubong Sabado .

Editor information

Editors and Affiliations

  1. Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA

    Sunil Thomas

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this protocol

Cite this protocol

Sabado, R.L., Meseck, M., Bhardwaj, N. (2016). Dendritic Cell Vaccines. In: Thomas, S. (eds) Vaccine Design. Methods in Molecular Biology, vol 1403. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3387-7_44

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-3387-7_44

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-3385-3

  • Online ISBN: 978-1-4939-3387-7

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation